可解脱弹簧圈栓塞治疗慢性硬膜下血肿 (SEED)
慢性硬膜下血肿可解脱弹簧圈栓塞治疗的安全性与有效性
This is a prospective, multi-center, post market registry study designed to evaluate the safety and efficacy of treatment with Balt coils in patients with chronic subdural hematoma (cSDH).
研究概览
详细说明
The primary objective of this observational registry study is to assess the safety and efficacy of Balt Coils as an adjunct to middle meningeal artery (MMA) embolization in a real-world setting among patients undergoing treatment for chronic subdural hematoma (cSDH), and explore correlations between patient characteristics, clinical characteristics, and outcomes. By collecting comprehensive, real-world data, the registry will characterize procedural inputs, document clinical and radiographic outcomes, and explore variation in technique and practice setting. The overarching goal is to generate a more complete understanding of Middle Meningeal Artery Embolization (MMAE) in diverse clinical environments, inform future prospective studies, and guide evidence-based adoption of this evolving therapy. Patients may be treated with Balt coils regardless of enrollment in the study as the decision to place the coils should be made independently as per standard of care and prior to enrollment in the study.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Sukaina Davdani
- 电话号码:(212) 241-2524
- 邮箱:Sukaina.Davdani@mountsinai.org
研究联系人备份
- 姓名:Sydney Edwards
- 电话号码:(212) 241-2524
- 邮箱:Sydney.Edwards@mountsinai.org
学习地点
-
-
Arizona
-
Tucson、Arizona、美国、85711
- 尚未招聘
- Carondelet Neurological Institute
-
首席研究员:
- Alexander Coon, MD
-
接触:
- Matthew Pohlmeyer
- 邮箱:Matthew.Pohlmeyer@tenethealth.org
-
-
California
-
San Deigo、California、美国、92093
- 尚未招聘
- University of California - San Deigo
-
接触:
- Pete Chase
- 邮箱:PChase@Health.UCSD.edu
-
首席研究员:
- David Santiago-Dieppa, MD
-
Walnut Creek、California、美国、94598
- 招聘中
- John Muir Health
-
首席研究员:
- Benjamin Yim, MD
-
接触:
- Melenie Aaron
- 邮箱:Melenie.Aaron@JohnMuirHealth.com
-
-
Kentucky
-
Louisville、Kentucky、美国、40292
- 尚未招聘
- University of Louisville
-
接触:
- Mechelle Kaufman
- 邮箱:Mechelle.Kaufman@louisville.edu
-
首席研究员:
- Isaac Josh Abecassis, MD
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 尚未招聘
- Oklahoma University Medical Center
-
首席研究员:
- Hakeem Shakir, MD
-
接触:
- Michael Omimi
- 邮箱:Michael-Omini@OU.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with symptomatic chronic subdural hematoma (cSDH), with or without previous surgical evacuation that need additional treatment
描述
Inclusion criteria:
- Age ≥ 18
- Patients experiencing unilateral or bilateral non-acute subdural hematoma confirmed by CT imaging. Acute on Chronic or mixed density hematoma allowed.
- A clinical decision has been made to use coiling and/or embolics as treatment, with or without surgical debridement, independently as per standard of care and prior to enrollment in the study.
- Signed informed consent obtained by patient or Legal Authorized Representative (LAR)
Exclusion criteria:
- Primary acute SDH
- Prior MMAE in target territory
- Premorbid mRS > 3
- Common carotid stenosis >70% or prior carotid stent placement
- Significant medical contraindication to angiography (kidney failure/disease)
- Anatomical variations that would make MMA embolization difficult or unsafe
- Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints
- Pregnancy
- Life expectancy ≤ 1 year
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Participants with cSDH
All participants enrolled will be treated with the Balt coils.
|
MMA embolization utilizing Balt Coils
其他名称:
surgical or bedside evacuation pre or post-surgical debridement |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in hematoma volume
大体时间:180 days
|
Change in hematoma volume based on CT imaging |
180 days
|
|
Change in maximal thickness
大体时间:180 days
|
Change in maximal thickness based on CT imaging |
180 days
|
|
Change in midline shift
大体时间:180 days
|
Change in midline shift (mm) based on CT imaging |
180 days
|
|
Number of periprocedural major disabling stroke or any death
大体时间:30 days
|
Number of periprocedural major disabling stroke or any death |
30 days
|
|
Number of participants with symptomatic recurrence progression requiring retreatment
大体时间:180 days
|
Number of participants with symptomatic recurrence progression of the SDH requiring retreatment |
180 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Device-related adverse events (AE), serious adverse events (SAE), and procedural-related SAE
大体时间:180 days
|
Number of Adverse events and serious adverse events related to the device as assessed by an independent medical monitor |
180 days
|
|
Number of Acute successful embolization of the target vessel
大体时间:Immediately post-procedure
|
Determination of successful embolization based on angiographic imaging |
Immediately post-procedure
|
|
Change in EuroQoL 5 dimensions 5 levels (EQ-5D-5L)
大体时间:180 days
|
The EQ-5D is a generic instrument for describing and valuing health. The new version includes the 5 levels of severity in each of the existing five EQ-5D dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and now called the EQ-5D-5L, each assessed on a 5-point scale (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems). Participants score each dimension based on their health that day and their responses are used to generate a health index score. Index scores could range from <0 (a health state equivalent to dead with negative values representing a state worse than dead) to 1 (full health). Lower scores indicate a higher QoL. |
180 days
|
合作者和调查者
调查人员
- 首席研究员:Christopher Kellner、Icahn School of Medicine at Mount Sinai
- 首席研究员:Benjamin Yim、John Muir Health
- 首席研究员:Alexander Coon、Carondelet Neurological Institute
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- STUDY-25-01365
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. Data that will be shared and published will be that of all participants combined to protect individual patient privacy and confidentiality.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.